GB0301701D0 - Psoriasis and Eicosapentaenoic acid - Google Patents
Psoriasis and Eicosapentaenoic acidInfo
- Publication number
- GB0301701D0 GB0301701D0 GBGB0301701.9A GB0301701A GB0301701D0 GB 0301701 D0 GB0301701 D0 GB 0301701D0 GB 0301701 A GB0301701 A GB 0301701A GB 0301701 D0 GB0301701 D0 GB 0301701D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- psoriasis
- eicosapentaenoic acid
- eicosapentaenoic
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000004681 Psoriasis Diseases 0.000 title 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 title 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0301701.9A GB0301701D0 (en) | 2003-01-24 | 2003-01-24 | Psoriasis and Eicosapentaenoic acid |
| PCT/GB2004/000242 WO2004064716A2 (en) | 2003-01-24 | 2004-01-22 | Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0301701.9A GB0301701D0 (en) | 2003-01-24 | 2003-01-24 | Psoriasis and Eicosapentaenoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0301701D0 true GB0301701D0 (en) | 2003-02-26 |
Family
ID=9951772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0301701.9A Ceased GB0301701D0 (en) | 2003-01-24 | 2003-01-24 | Psoriasis and Eicosapentaenoic acid |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0301701D0 (en) |
| WO (1) | WO2004064716A2 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5491697B2 (en) * | 2004-10-15 | 2014-05-14 | フォトンズ コーポレイション リミテッド | Composition comprising high level omega-3 and low level saturated fatty acids |
| WO2008004900A1 (en) | 2006-07-05 | 2008-01-10 | Photonz Corporation Limited | Production of ultrapure epa and polar lipids from largely heterotrophic culture |
| US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| ES2561482T3 (en) | 2007-02-15 | 2016-02-26 | Centre De Recherche Sur Les Biotechnologies Marine | Monoglycerides of polyunsaturated fatty acid, derivatives, and their uses |
| AU2008229604B2 (en) | 2007-03-20 | 2013-05-30 | Scf Pharma Inc. | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| WO2008119146A2 (en) * | 2007-03-29 | 2008-10-09 | Dair, Bicudo Piai | Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd |
| US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| WO2010127099A2 (en) | 2009-04-29 | 2010-11-04 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| SG10201605794PA (en) | 2009-04-29 | 2016-09-29 | Amarin Pharmaceuticals Ie Ltd | Stable Pharmaceutical Composition And Methods Of Using Same |
| CN108096209A (en) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | Triglycerides, composition and method without increasing LDL-C levels are reduced in the object of associated Statins therapy |
| WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| EP2646013A4 (en) | 2010-11-29 | 2014-03-26 | Amarin Pharma Inc | LOW-ERUCATION COMPOSITION AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASE IN A SUBJECT HAVING FISH ALLERGY / HYPERSENSITIVITY |
| WO2013063067A1 (en) * | 2011-10-24 | 2013-05-02 | Stable Solutions Llc | Enriched injectable emulsion containing selected fatty acid triglycerides |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| JP6307442B2 (en) | 2012-01-06 | 2018-04-04 | アマリン ファーマシューティカルス アイルランド リミテッド | Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject |
| WO2013150384A1 (en) * | 2012-04-04 | 2013-10-10 | Pronova Biopharma Norge As | Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof |
| CA2916208A1 (en) | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
| SMT202500326T1 (en) | 2012-06-29 | 2025-11-10 | Amarin Pharmaceuticals Ie Ltd | Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal stroke in a subject on statin therapy |
| JP2016500055A (en) * | 2012-10-23 | 2016-01-07 | ディーキン・ユニバーシティー | Method for reducing triglycerides |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| CA3055225A1 (en) | 2018-02-07 | 2019-08-15 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| CN112384212A (en) | 2018-05-03 | 2021-02-19 | Scf制药股份有限公司 | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| EP3700518A4 (en) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | METHODS FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT |
| US12226390B2 (en) | 2019-07-21 | 2025-02-18 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| CN114980973A (en) | 2019-11-12 | 2022-08-30 | 阿马里纳药物爱尔兰有限公司 | Method for reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| EP4326244A4 (en) | 2021-04-21 | 2025-03-19 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244921A (en) * | 1990-03-21 | 1993-09-14 | Martek Corporation | Eicosapentaenoic acids and methods for their production |
| JP3689137B2 (en) * | 1994-08-19 | 2005-08-31 | 俊之 渡辺 | Topical agent for treatment of allergic skin disease |
| CN1125651C (en) * | 1998-04-16 | 2003-10-29 | 欧维塔有限公司 | Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| GB0111282D0 (en) * | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
-
2003
- 2003-01-24 GB GBGB0301701.9A patent/GB0301701D0/en not_active Ceased
-
2004
- 2004-01-22 WO PCT/GB2004/000242 patent/WO2004064716A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004064716A2 (en) | 2004-08-05 |
| WO2004064716A3 (en) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0301701D0 (en) | Psoriasis and Eicosapentaenoic acid | |
| EP1660427A4 (en) | Substituted arylalkanoic acid derivative and use thereof | |
| IL163957A0 (en) | Monocyclic aroylpyridinones as antiinflammatory agents | |
| IL172617A0 (en) | Biaryloxymethylarene-carboxylic acids | |
| AU2003236991A8 (en) | Representations of processes | |
| EP1551384A4 (en) | R-nsaid esters and their use | |
| EP1511488A4 (en) | Human adam-10 inhibitors | |
| TW595562U (en) | Casket | |
| GB0223127D0 (en) | nanoparticles | |
| HRP20041101A2 (en) | New etonogestrel esters | |
| EP1617830A4 (en) | Esterified fatty acid composition | |
| ZA200508388B (en) | Macrolide-Conjugates with anti-inflammatory activity | |
| GB0223149D0 (en) | Nanoparticles | |
| GB2415628B (en) | Catheters | |
| GB2401094B (en) | Labels and methods of manufacture thereof | |
| ZA200505679B (en) | Nutritional formula comprising L(+)-lactic acid | |
| AU2003222065A8 (en) | Chemiluminescent treatment of acne | |
| EP1525852A4 (en) | Catheter | |
| GB0223650D0 (en) | Psoriasis treatment | |
| AU2003286392A8 (en) | 1microarrays and production thereof | |
| GB0223783D0 (en) | Didgeridoo manufacture | |
| AU2003251456A1 (en) | N-bisaryl- and n-aryl-cycloalkylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides | |
| AU2764P (en) | Lorraine Anubias barteri | |
| GB0312028D0 (en) | Manufacture of signs | |
| GB0204870D0 (en) | Trts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| COOA | Change in applicant's name or ownership of the application |
Owner name: PABAY INVESTMENTS LIMITED Free format text: FORMER APPLICANT(S): ENSAY LIMITED |
|
| AT | Applications terminated before publication under section 16(1) |